2018 American Transplant Congress
Diagnostic Accuracy of Non-Invasive Test of Hepatic Fibrosis in Liver Transplant Recipients
Background & Aims: Hepatic fibrosis is an important predictor of liver- and non-liver related outcomes in patients with chronic liver disease (CLD) and liver transplantation…2018 American Transplant Congress
National Landscape of HIV+ Liver Transplant Candidates
1JHU, Baltimore; 2SRTR, Minneapolis; 3UAB, Birmingham.
The annual number of HIV+ liver transplant (LT) recipients has increased >10-fold since 2002. However, candidate HIV-status is not collected by UNOS, and the national…2018 American Transplant Congress
Impact of Direct Acting Antiviral Agents (DAAs) for Hepatitis C Virus (HCV)-Induced Liver Diseases on Registration and Outcome on Waiting List (WL) for Liver Transplant (LT)
2d-generation DAAs have dramatically improved the management of patients with HCV, including patients with advanced diseases. In France, since 2013, DAA have been largely used,…2018 American Transplant Congress
Impact of Direct Antiviral Therapy for Hepatitis C on Acute Rejection and DSA Formation in Kidney Transplant Recipients
Cleveland Clinic, Cleveland, OH.
Background: Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With recent advent of direct antiviral agents (DAA), there has…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis
Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…2018 American Transplant Congress
Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation
Effective treatment for hepatitis C virus (HCV) infection has revolutionized post liver transplant (LTx) care. Administration of direct-acting antiviral agents (DAAs) after HCV+ LTx results…2018 American Transplant Congress
Elbasvir-Grazoprevir (Zepatier) is Effective and Safe for the Treatment of Chronic Hepatitis C (HCV) Genotype 1 Virus in the Post Kidney Transplant Patient
Objective: Limited real world data exists regarding the use of direct acting antivirals (DAA) for HCV viremia in renal transplant patients, particularly those with marked…2018 American Transplant Congress
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…2018 American Transplant Congress
One-Year Outcomes in Patients with Advanced Liver Fibrosis or Compensated Cirrhosis from Chronic Hepatitis C Receiving Kidney Transplant Alone
Background: Hepatitis C (HCV) was difficult to treat post-kidney transplant prior to the direct acting antiviral (DAA) era. As such patients with advanced fibrosis and…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 28
- Next Page »